Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10741565rdf:typepubmed:Citationlld:pubmed
pubmed-article:10741565lifeskim:mentionsumls-concept:C0239045lld:lifeskim
pubmed-article:10741565lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:10741565lifeskim:mentionsumls-concept:C0035309lld:lifeskim
pubmed-article:10741565lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:10741565lifeskim:mentionsumls-concept:C0002003lld:lifeskim
pubmed-article:10741565lifeskim:mentionsumls-concept:C0449258lld:lifeskim
pubmed-article:10741565lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:10741565lifeskim:mentionsumls-concept:C0456962lld:lifeskim
pubmed-article:10741565pubmed:issue3lld:pubmed
pubmed-article:10741565pubmed:dateCreated2000-5-19lld:pubmed
pubmed-article:10741565pubmed:abstractTextA recent case-control study suggests that the allele (AC)23 of a variable number tandem repeat (VNTR) associated to the aldose reductase (ALR2) gene could be related to early retinopathy in Type 2 diabetics. By means of a longitudinal-retrospective study, we aimed to seek for a relationship between the rate of progression of retinopathy and the (AC)23 allele of the VNTR associated to the ALR2 gene. A random sample was obtained of 27 Type 2 diabetics (aged 68.1 +/- 10.6 years, diabetes duration = 20.7 +/- 4.8 years, mean HbA1 = 10.6 +/- 1.6%). The mean HbA1 was the arithmetic average of 2.2 measurements per patient per year of total glycosilated hemoglobin (Gabbay method, normal range: 4.2-7.5%). Retinopathy was graded by an Ophthalmologist in a scale from zero to four score points. The genotype of the (AC), VNTR was determined by 32P-PCR plus sequenciation in a Perkin-Elmer laser device. The Mann-Whitney test and either chi2 or Fisher's exact test were used. A P < 0.05 was considered as statistically significant. The retinopathy progression rate (RPR, points x year(-1)) was calculated by dividing the increment of retinopathy score (delta Retinopathy Score, [points]), by the duration of the follow up [years]. The 12 diabetics having the (AC)23 allele had a mean RPR 8.9 times higher (0.40 +/- 0.61 points x year(-1)) than the 15 patients who had alleles other than (AC)23 (0.045 +/- 0.099 points x year(-1), P = 0.037). Both groups were similar with respect to: mean HbA1 (10.5 +/- 1.4 and 10.7 +/- 1.7%, P = 0.95), age at diagnosis (48.5 +/- 6.3 and 46.3 +/- 14.0 years, P = 0.81), diabetes' duration (21.3 +/- 4.7 and 20.2 +/- 4.9 years, P = 0.41) and serum creatinine (0.89 +/- 0.2 and 1.13 +/- 0.5 mg dl(-1), P = 0.35). We concluded that, in Type-2 diabetics having similar glycemic control, the (AC)23 allele of the VNTR associated to the ALR2 gene, is associated to a 8.9 times faster progression of retinopathy than in patients who have other alleles.lld:pubmed
pubmed-article:10741565pubmed:languageenglld:pubmed
pubmed-article:10741565pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10741565pubmed:citationSubsetIMlld:pubmed
pubmed-article:10741565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10741565pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10741565pubmed:statusMEDLINElld:pubmed
pubmed-article:10741565pubmed:monthMarlld:pubmed
pubmed-article:10741565pubmed:issn0168-8227lld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:SiegelSSlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:EmmerichMMlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:DíazRRlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:MoralesPPlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:AcostaA MAMlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:MaizAAlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:ArriagadaPPlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:OlmosPPlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:VeghKKlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:VelascoSSlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:VollrathVVlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:SchiaffinoRRlld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:ClaroJ CJClld:pubmed
pubmed-article:10741565pubmed:authorpubmed-author:FutersSSlld:pubmed
pubmed-article:10741565pubmed:issnTypePrintlld:pubmed
pubmed-article:10741565pubmed:volume47lld:pubmed
pubmed-article:10741565pubmed:ownerNLMlld:pubmed
pubmed-article:10741565pubmed:authorsCompleteYlld:pubmed
pubmed-article:10741565pubmed:pagination169-76lld:pubmed
pubmed-article:10741565pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:meshHeadingpubmed-meshheading:10741565...lld:pubmed
pubmed-article:10741565pubmed:year2000lld:pubmed
pubmed-article:10741565pubmed:articleTitle(AC)23 [Z-2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics.lld:pubmed
pubmed-article:10741565pubmed:affiliationDepartment of Nutrition, Diabetes and Metabolism, College of Medicine, Pontificia Universidad Católica de Chile, Santiago. polmos@med.puc.cllld:pubmed
pubmed-article:10741565pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10741565pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10741565lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10741565lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10741565lld:pubmed